Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × isoquercitrin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Fatigue 1 Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 33 Paclitaxel 27 Carboplatin 25 Gemcitabine 24 Nivolumab 22 Cisplatin 22 camrelizumab 20 Capecitabine 20 fludarabine 19 apatinib 18 Oxaliplatin 17 Immunotherapy, Adoptive 17 toripalimab 16 pembrolizumab 15 Radiotherapy 15 Drug Therapy 14 Bevacizumab 14 Rituximab 13 tislelizumab 12 Temozolomide 12 Docetaxel 12 Dexamethasone 11 Cetuximab 11 Irinotecan 10 Injections 10 Cytarabine 10 anlotinib 9 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9 130-nm albumin-bound paclitaxel 9 Trastuzumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02446795 2017-01-18

QUASAR

Consorzio Oncotech

Phase 1/2 Unknown

Carcinoma, Renal Cell, Fatigue, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡